Mirum Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MIRM | IONS | TVTX | BMRN | ARWR | RARE | |
|---|---|---|---|---|---|---|
| Market cap | 5.59B | 7.26B | 4.90B | 10.72B | 8.58B | 1.51B |
| P/E (TTM) | — | — | — | 149.7 | — | — |
| Forward P/E | -248.2 | -39.3 | 9.2 | 8.3 | -12.3 | 25.8 |
| Price/book | -534.5 | 16.4 | 200.1 | 1.7 | 18.4 | -5.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +19.18% | −35.85% | +98.95% | +4.48% | +68.88% | −51.66% |
| Today | +0.06% | −3.56% | −0.20% | +1.09% | −3.22% | −1.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MIRM news ›Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia October 12, 2026 8:30 AM EDT Andrew McKibben - Senior Vice President, Strategic Finance & Investor…
Mirum Pharmaceuticals to report Livmarli trial results Monday
(MIRM:NASDAQ) Seeking Alpha Grandbrothers/iStock Editorial via Getty Images Mirum Pharmaceuticals (MIRM) said it will release topline results from a late-stage clinical trial of its Livmarli treatment on Monday, October 12, providing…
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p - Mirum plans U.S. sNDA submission in the first half of…
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FinancialContent Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading…
Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases
Seeking Alpha kitiwan mesinsom/iStock via Getty Images - Mirum Pharmaceuticals (MIRM) said that a phase 3 trial of Livmarli (maralixibat) for cholestatic pruritus (severe itching) associated with impaired bile flow in patients six months…
Mirum reports LIVMARLI Phase 3 trial success
Assets related to this article Mirum Pharmaceuticals (NASDAQ:MIRM) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) in patients aged 6 months and older with ultra-rare cholestatic liver diseases,…
Mirum tees up Livmarli label expansion on Phase III liver disease study success
If given the FDA blessing, Livmarli could become indicated in the US for the treatment of ultra-rare liver diseases like biliary atresia. Mirum Pharmaceuticals’ marketed therapy, Livmarli (maralixibat), could be poised for a label…
Mirum’s Phase III EXPAND Study of Livmarli meets goal - The Pharma Letter
Mirum’s Phase III EXPAND Study of Livmarli meets goal The Pharma Letter
Wilmington’s Incyte and Mirum Pharmaceuticals Win FDA Approval of Atebrioz™ for Ultra-Rare Bone Disease FOP
Incyte, the Wilmington, Delaware-based biopharmaceutical company, and Mirum Pharmaceuticals, announced on September 25, 2026 that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
seekingalpha.com4
-
financialcontent.com2
-
stocktitan.net2
-
themarketsdaily.com2
-
contractpharma.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.